ERBB2 and breast carcinoma: On the basis of the results of two clinical trials, EMILIA6,7,9 and TH3RESA8,13, T-DM1 has become accepted as the standard of treatment for HER2-positive breast cancer, both as second- or further-line treatment for advanced or metastatic disease and as first-line treatment in the case of early progression to adjuvant treatment.